



Suggested Formula	Zolpidem Tartrate 5 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 003 282v4
-------------------	--------------------------------------------------------------	-----	-------------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Zolpidem Tartrate (10 mg) Tablets	10	Units				
Glycerin, USP	5.0	mL				
Raspberry Flavor (Concentrate)	0.1	mL				
Medisca Oral Suspend (Suspending Vehicle)	50.0	mL				
Medisca Oral Syrup (Flavored Vehicle)	q.s. to 100.0	mL				

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Controlled substance (adhere to proper handling and documentation procedures) Zolpidem Tartrate

Hygroscopic (protect from moisture whenever possible): Glycerin

Suggested Preparatory Guidelines

Non-Sterile Preparation Sterile Preparation

Processing Error / Testing Considerations: To account for processing error considerations during preparation, it is suggested to measure an additional **5 to 9%** of the required quantities of ingredients.

Special Instruction: Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



Suggested Formula	Zolpidem Tartrate 5 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 003 282v4
-------------------	--------------------------------------------------------------	-----	-------------

SUGGESTED PREPARATION (for 100 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor ^(*) : _____	Processing Error	Qty. to measure
Zolpidem Tartrate (10 mg) Tablets	10	Units			
Glycerin, USP §	5.0	mL			
Raspberry Flavor (Concentrate)	0.1	mL			
Medisca Oral Suspend (Suspending Vehicle)	50.0	mL			
Medisca Oral Syrup (Flavored Vehicle)	q.s. to 100.0	mL			

§ Weigh / measure just prior to use.

* Takes into account increased batch size conversions and density conversions, if required.





Suggested Formula	Zolpidem Tartrate 5 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 003 282v4
-------------------	--------------------------------------------------------------	-----	-------------

Preparatory Instruction

1. Ingredient quantification (determine the actual quantity of Zolpidem Tartrate (10 mg) tablet powder mix to weigh):

A. Weigh 11 Zolpidem Tartrate (10 mg) Tablets. Record the total weight here: _____ g

B. Calculate the average weight of powder in each tablet:

Weight of 11 tablets (from Step 1A):	_____ g
DIVIDED BY	
Number of tablets:	11
EQUALS	
Average weight of a single Zolpidem Tartrate (10 mg) Tablet:	_____ g

C. Calculate the weight of powder equivalent to 10 tablets:

Average weight of a single Zolpidem Tartrate (10 mg) Tablet (from Step 1B):	_____ g
MULTIPLIED BY	
Number of tablets required:	10
EQUALS	
Weight of powder equivalent to 10 tablets:	_____ g

D. Calculate the weight of powder required *plus* processing error adjustments:

Weight of powder equivalent to 10 tablets (from Step 1C):	_____ g
MULTIPLIED BY	
Processing error adjustments (5 to 9%):	1.05 to 1.09
EQUALS	
Weight of powder required <i>plus</i> processing error adjustments:	_____ g



Suggested Formula	Zolpidem Tartrate 5 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 003 282v4
2.	<p><u>Powder preparation:</u></p> <p>A. Crush and triturate the 11 Zolpidem Tartrate (10 mg) Tablets into a fine homogeneous powder.</p> <p>B. Weigh the quantity of Zolpidem Tartrate (10 mg) tablet powder mix required for the batch (refer to Step 1D) and discard the remaining powder.</p>		
3.	<p><u>Powder-liquid preparation:</u></p> <p>A. Levigate the Zolpidem Tartrate (10 mg) tablet powder mix (amount weighed in Step 2B) with the Glycerin.</p> <p><u>End result:</u> Homogeneous paste-like dispersion.</p>		
4.	<p><u>Medium preparation:</u></p> <p>A. Combine and mix the following ingredients together:</p> <ul style="list-style-type: none">-Oral Suspend (Suspending Vehicle)-Raspberry Flavor (Concentrate) <p><u>End result:</u> Homogeneous liquid-like dispersion.</p>		
5.	<p><u>Powder-liquid to medium integration:</u></p> <p>A. Incrementally add the homogeneous paste-like dispersion (Step 3A) to the homogeneous liquid-like solution (Step 4A)</p> <p><u>Specifications:</u> Continuously mix, using high-shear mixing techniques.</p> <p><u>End result:</u> Homogeneous liquid-like dispersion.</p>		
6.	<p><u>Filling to volume:</u></p> <p>A. Add Oral Syrup (Flavored Vehicle) to the mixture (Step 5A) to fill to the required batch size (100.0 mL <i>plus</i> processing error adjustments).</p> <p><u>Specifications:</u> Continuously mix.</p> <p><u>End result:</u> Homogeneous liquid-like dispersion.</p>		
7.	<p><u>Product transfer:</u></p> <p>A. Transfer the final product into the specified dispensing container (see “Packaging requirements”).</p> <p><u>Note:</u> Continuously mix the final product during the transfer process into the recommended dispensing containers in order to maintain homogeneity.</p>		



Suggested Formula	Zolpidem Tartrate 5 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 003 282v4
-------------------	--------------------------------------------------------------	-----	-------------

SUGGESTED PRESENTATION

Estimated Beyond-Use Date	14 days, refrigerated, as per USP.	Packaging Requirements	- Tightly closed dispensing bottle. - To be administered with a metered dose-measuring device.	
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	6	Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.
	2	Keep out of reach of children.	7	Cap tightly after use.
	3	Shake well before use.	8	Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.
	4	Keep refrigerated. Do not freeze.	9	Controlled substance. Dangerous unless used as directed.
	5	May impair mental and/or physical ability. Use care when operating a car or machinery.	10	May produce psychological and/or physical dependence.
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.			
Patient Instructions	Contact your pharmacist in the event of adverse reactions.			

REFERENCES

1.	Flavors, Sweeteners, and Colors. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Third Edition</i> . American Pharmaceutical Association; 2008: 89.
2.	Glycerin. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 4th Edition</i> . American Pharmaceutical Association; 2003: 257.
3.	Zolpidem (Monograph). In: O'Neil MJ. <i>The Merck Index 14th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #10190.
4.	Zolpidem. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional, 26th Edition</i> . Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 3014.
5.	USP <795>. <i>United States Pharmacopeia XXXI / National Formulary 26</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2008.

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.